| Title | Inhibition of B virus (Cercopithecine herpesvirus 1) by Conventional and Experimental Antiviral Compounds. | | Author(s) | Krug PW, Schinazi RF, Hilliard JK | | Institution | Viral Immunology Center, Georgia State University, and Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia. | | Source | Antimicrob Agents Chemother 2009 Oct 26. | | Abstract | B virus infection of humans results in high morbidity and mortality in up to 80% of identified cases. The main objective of this study was to conduct a comparative analysis of conventional and experimental antiviral drug susceptibilities of B virus isolates from multiple macaque species and zoonotically infected humans. We used a plaque reduction assay to establish the effective inhibitory doses of acyclovir, ganciclovir, and vidarabine, as well as a group of experimental nucleoside analogs with known anti-herpes simplex virus activity. Four of the tested experimental drugs were 10 to 100-fold more potent inhibitors of B virus replication than conventional antiviral agents. Drug efficacy was similar for multiple B virus isolates tested with variations within 2-fold of the median effective concentration (EC50) for each drug and was considerably lower than those of B virus TK mutants. We observed no differences in the viral thymidine kinase amino acid sequence between B virus isolates from rhesus monkeys and human zoonoses. Differences in the TK protein sequence of cynomolgus and pigtail macaque B virus isolates did not affect drug sensitivity except in the case of one compound. Taken together, these data suggest that future B virus zoonoses will respond consistently to conventional antiviral treatment. Further, the considerably higher potency of FEAU advocates its compassionate use in advanced human B virus infections. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19858259 |
|
